Record’s passive currency hedging offers institutional investors a low-friction way to reduce FX risk and smooth cash flows without taking market positions...
Fidelity Emerging Markets achieved a NAV total return of 34.3% and a share price return of 40.3% for the year to 30 September 2025, outperforming the MSCI EM Index...
Avation plc’s Jeff Chatfield explains the rationale behind their new $300 million bond issue, upgraded credit ratings, and why a 16-year widebody lease is a milestone for the company...
Marshalls, the sustainable building products manufacturer, recorded Group revenue of £548m for the ten months to 31 October 2025, up 2% year-on-year...
BAE Systems plc (LON:BA) has announced its latest trading update. Highlights: · Strong operational and financial performance underpins Group full-year guidance, in line with upgrade at half year. · Positive momentum in..
SSE plc has announced interim results for the six months to 30 September 2025, with performance in line with expectations and adjusted earnings per share of 36.1p...
Nuformix has received an FDA request for clarification on its Orphan Drug Designation application for tranilast under the NXP002 programme. The company also reported its Open Offer was oversubscribed by..
Record’s passive currency hedging offers institutional investors a low-friction way to reduce FX risk and smooth cash flows without taking market positions...
Fidelity Emerging Markets achieved a NAV total return of 34.3% and a share price return of 40.3% for the year to 30 September 2025, outperforming the MSCI EM Index...
Avation plc’s Jeff Chatfield explains the rationale behind their new $300 million bond issue, upgraded credit ratings, and why a 16-year widebody lease is a milestone for the company...
Marshalls, the sustainable building products manufacturer, recorded Group revenue of £548m for the ten months to 31 October 2025, up 2% year-on-year...
SSE plc has announced interim results for the six months to 30 September 2025, with performance in line with expectations and adjusted earnings per share of 36.1p...
Nuformix has received an FDA request for clarification on its Orphan Drug Designation application for tranilast under the NXP002 programme. The company also reported its Open Offer was oversubscribed by 408%, raising around £228,000 before expenses...
